Notice2021-17687
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 18, 2021
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 157 (Wednesday, August 18, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 157 (Wednesday, August 18, 2021)]
[Notices]
[Pages 46258-46259]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-17687]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Elizabeth Pitts, Ph.D., 240-669-5299;
<a href="/cdn-cgi/l/email-protection#e7828b8e9d868582938fc9978e939394a7898e8fc9808891"><span class="__cf_email__" data-cfemail="cda8a1a4b7acafa8b9a5e3bda4b9b9be8da3a4a5e3aaa2bb">[email protected]</span></a>. Licensing information may be obtained by
communicating with the indicated licensing contact at the Technology
Transfer and Intellectual Property Office, National Institute of
Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD
20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement
will be required to receive copies of unpublished information related
to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows.
Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing
Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication
Compared to the Model Huh7.5 Cell Line
Description of Technology
Worldwide, 130-150 million individuals are chronically infected
with hepatitis C virus (HCV), a major cause of liver-associated
morbidity and mortality worldwide. Despite recent advances in antiviral
drugs that can cure some individuals, a rapid decline of the
[[Page 46259]]
global disease burden is hampered by remarkably high treatment costs
and a high number of undiagnosed infections. Moreover, a significant
number of patients develop resistance and additional treatment
modalities may be needed to dramatically reduce the worldwide incidence
of HCV infection. The subject cell line may be a useful tool for
studying the mechanism of HCV cellular entry and replication and could
be incorporated into an in vitro assay to measure the effectiveness of
novel HCV targeted therapies or as a system for improved propagation of
HCV in culture.
By overexpressing TACSTD2 in Huh7.5 cells, scientists at the
National Institute of Allergy and Infectious Diseases (NIAID)
discovered that they could restore the cellular localization of two
host cell HCV-entry factors that become dysregulated in hepatocellular
carcinoma (HCC) cells. Overexpression of TACSTD2 makes Huh7.5 cells
more broadly permissive to infection and replication by multiple HCV
genotypes in comparison to the canonical Huh7.5 cell model. HCV does
not replicate in malignant HCC cells, possibly caused in part by
downregulation of TACSTD2 expression.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
Potential Commercial Applications
<bullet> Cell line to study hepatitis C virus infection and
replication or propagate HCV in culture.
<bullet> Cell line to study cancer.
Development Stage
<bullet> Material.
Inventors: Patrizia Farci and Vandana Sekhar (NIAID).
Publication: Sekhar V, Pollicino T, Diaz G, Engle RE, Alayli F,
Melis M, Kabat J, Tice A, Pomerenke A, Altan-Bonnet N, Zamboni F, Lusso
P, Emerson SU, and Farci P. (2018) Infection with hepatitis C virus
depends on TACSTD2, a regulator of claudin-1 and occludin highly
downregulated in hepatocellular carcinoma. PLoS Pathog 14: e1006916.
doi: 10.1371/journal.ppat.1006916.
Licensing Contact: To license this technology, please contact
Elizabeth Pitts, Ph.D., 240-669-5299; <a href="/cdn-cgi/l/email-protection#07626b6e7d666562736f29776e73737447696e6f29606871"><span class="__cf_email__" data-cfemail="3d585154475c5f584955134d5449494e7d535455135a524b">[email protected]</span></a>, and
reference E-040-2020.
Dated: August 12, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-17687 Filed 8-17-21; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on August 18, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.